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The most commonly used topical pharmacologic agents 
for symptomatic management of hemorrhoids include 
vasoconstrictors, astringents, anesthetics, keratolytics, 
corticosteroids, and antipruritic agents. Some of these drugs 
have been involved in contact dermatitis [1-7]. 
A 57-year-old woman presented with a pruritic, sharply 
demarcated, erythematous rash on the anogenital area that 
spread within 2-3 days to the trunk, neck, forearms, groins, and 
upper inner aspect of the thighs. The rash began 3 to 4 days 
after application of an antihemorrhoidal ointment (Ruscus 
Llorens, Llorens, Barcelona, Spain) containing ruscogenin, 
prednisolone, cinchocaine, menthol, zinc oxide, and excipients 
(a mixture of parabens [methyl, ethyl, and butyl], polyethylene 
glycol, and cetyl alcohol). Avoidance of the antihemorrhoidal 
ointment and treatment with topical and oral corticosteroids 
and oral antihistamines improved the lesions within 2 weeks. 
The patient denied previous exposure to the ointment and 
had no history of atopy or contact dermatitis. One month 
after the reaction, the patient tolerated varicose vein cream 
containing Ruscus aculeatus (its primary active ingredients 
are ruscogenins), Melilotus offi cinalis, zinc oxide, the paraben 
mixture (methyl, ethyl, and butyl), and sodium edetate.
Six weeks later, we performed patch tests using the 
Spanish Contact Dermatitis Research Group standard series 
and corticosteroid series, the antihemorrhoidal ointment as 
is, and all the individual components to which the patient had 
not been exposed to after the reaction (ie, ruscogenin 30% pet 
and 30% eth, prednisolone 1% pet, cinchocaine 5% pet, 
menthol 2% pet, polyethylene glycol 4% pet, and cetyl 
alcohol 5% pet). These concentrations were higher than in 
the ointment. Readings at 48 hours, 96 hours, and 1 week 
were negative for all of them. A repeated open application 
test (ROAT) was performed on the flexor forearm with 
the ointment as is and its individual components (2 daily 
applications for 7 days). Negative results were obtained with 
the individual components, but the result for the ointment was 
positive on the third day: erythema, papules, infi ltration, and 
pruritus appeared on the application area, although they all 
resolved within 7 days (Figure). The results of the same test 
performed on 5 control patients proved negative.
Figure. Repeated open application test with the ointment as is on the 
third day.
We report a case of generalized contact dermatitis due 
to an antihemorrhoidal ointment demonstrated by ROAT. 
Only the whole preparation caused the reaction, whereas the 
results of testing its individual ingredients were negative. 
The positive patch test results to a commercial product and 
negative results to its individual ingredients could indicate 
that the patient experienced a compound allergy. In some 
cases, a chemical interaction has been demonstrated between 
the ingredients within the whole preparation to form a new 
allergen, and in others, the authors suggest enhanced delivery 
of the allergen via the original preparation rather than the patch 
test vehicle [8]. We ruled out alternative explanations such 
as contamination of the ointment, an irritant reaction, or an 
insuffi cient concentration of individual ingredients for patch 
testing. The negative results of the patch test with the ointment 
applied on the back, and the positive results of the ROAT with 
the ointment applied on the forearm could be explained by the 
fact that the fi rst test does not reproduce the clinical exposure 
(multiple applications). In addition, it is diffi cult to reproduce 
the particular anatomical and pathological conditions of the 
anogenital area (ie, sweating, friction, pressure, damaged 
skin), which could increase skin penetration and the sensitizing 
capacity of pharmaceutical products [9]. Therefore, patch 
testing on the back may give false-negative results, especially 
when the product is applied to sites such as the anogenital area. 
Diagnosis of allergic contact dermatitis in these cases can be 
confi rmed by ROAT with the preparations used by the patient 
and their individual ingredients.
In conclusion, we report the fi rst case of systemic contact 
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dermatitis due to a compound allergic reaction to Ruscus 
Llorens ointment diagnosed by ROAT test.
These data were presented in part in abstract and poster 
form at the XXVII Congress of the EAACI, Barcelona, June 
7-11, 2008.
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Despite the huge increase in the use of sunscreens during 
recent years and the addition of ultraviolet (UV) fi lters to cosmetic 
products such as moisturizers and lipsticks, photoallergic contact 
dermatitis to these agents remains rare [1]. However, sunscreens 
have emerged as the most frequent cause of photoallergic 
reactions [2].
We report a case of photoallergic contact dermatitis to a 
UV fi lter, isoamyl-p-methoxycinnamate.
A 34-year-old woman attended the allergy unit after 2 
episodes of dermatitis during the previous 2 months. She 
experienced a symmetrical eczematous eruption on the face, 
neck, V-area of the upper chest, dorsum of the hands, forearms, 
and legs after application of sunscreen and exposure to the 
sun. She had no personal or family history of atopy. She was 
successfully treated with a reducing course of oral prednisone 
and topical hydrocortisone ointment for 3 weeks.
 Patch tests were performed using the standard series of 
the Spanish Contact Dermatitis Research Group (www.aedv.
es/res.asp). She was also tested with the photopatch series of 
the Spanish Photobiology Group [3], the sunscreen chemical 
series of the European Task Force for Photopatch Testing [4], 
and her own sunscreen. The methodology followed was that of 
the European protocol [4]. The only positive reactions were to 
isoamyl-p-methoxycinnamate and the patient’s own sunscreen, 
both of which occurred at D4 (+++) (Table). Her sunscreen 
contained isoamyl-p-methoxycinnamate. Unirradiated and 
irradiated controls were negative.
Table. Positive Results of Photopatch Testing in an Irradiated Set
  
 Agent D2  D2 D4
  Pre-irradiation Postirradiation Postirradiation 
 Isoamyl-p- 
 methoxycinnamate – – +++
 Patient’s own
 sunscreen – – +++
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A variety of topical agents have been associated with 
photoallergic contact dermatitis [5]. Antibacterial and antifungal 
agents were the fi rst described. In the 1960s and 1970s, the most 
sensitizing substances were salicylanilides, and in the 1970s 
and 1980s fragrances such as musk ambrette were prevalent 
causes. Both were withdrawn. More recently, active agents in 
sunscreens have been important causes of photoallergic contact 
dermatitis [6]. The most common UV fi lter photoallergens are 
benzophenones and p-aminobenzoic acid [1]. 
In recent years cinnamates have emerged as an alternative 
to p-aminobenzoic acid and benzophenones in Europe, the 
United States, Japan, and Australia [6]. The cinnamates are 
primarily UV-B absorbers. Given their poor water solubility, 
they are often used in sunscreens marketed as waterproof. 
Whereas allergy to cinnamate sunscreen ingredients is 
uncommon, cross-reactivity with fl avorings and fragrances that 
include balsam of Peru, coca leaves, cinnamic acid, cinnamic 
aldehyde, and cinnamon oils is more signifi cant [7]. 
We report a case of photoallergic contact dermatitis to isoamyl-
p-methoxycinnamate. The prevalence of this condition may increase 
as sunscreen use becomes more widespread. The pattern of reactions 
to active sunscreen agents is also changing, and proper identifi cation 
of the sunscreen allergen is very important. Photopatch test series 
should be regularly reviewed and updated.
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Allergic bronchopulmonary aspergillosis (ABPA) 
was first described in 1952 [1]. Since then, other fungi 
that produce diseases with similar presentations to ABPA 
have been described. These diseases are known as allergic 
bronchopulmonary mycoses (ABPM). Candida albicans has 
been reported as a causative agent in ABPM [2-5]. 
Traditionally, the treatment of ABPM has been based 
on corticosteroids and, occasionally, antifungal drugs. We 
present a case of allergic bronchopulmonary candidiasis 
(ABPC) that was successfully treated with a recombinant 
anti–immunoglobulin (Ig) E antibody (omalizumab).
A 59-year-old man fi rst attended our pneumology unit in 
2005 with dyspnea on moderate exertion, purulent sputum, 
and nocturnal wheezing. Spirometry prior to initiation of 
treatment showed a forced vital capacity (FVC) of 2600 mL 
(61%) and a forced expiratory volume in 1 second (FEV
1
) 
of 1540 mL (45%) with a positive bronchodilator test result. 
Short-acting and long-acting ß
2
-agonists, leukotriene receptor 
antagonists, and corticosteroids (inhaled and oral) were 
prescribed. Despite this treatment, he was hospitalized 3 times 
in 2 years due to acute exacerbations of his symptoms and 
developed pulmonary infi ltrates and peripheral bronchiectasia. 
After a 2-year follow-up, he was diagnosed with severe, 
persistent, and corticosteroid-dependent asthma. At this time, 
spirometry showed an FVC of 3250 mL (84%) and an FEV
1 
of 2490 mL (74%). Therefore, omalizumab was added to his 
treatment regimen. He was also referred to the allergy unit for 
an allergologic work-up. After in vivo and in vitro tests, the 
patient met the criteria for ABPC [5] (Table). Furthermore, 
a significant improvement in respiratory symptoms and 
pulmonary function (FVC, 4070 mL [97.5%]; FEV
1
, 2730 mL 
[82.5%]) was observed when omalizumab was administered. 
Oral corticosteroids were no longer necessary after 3 months 
under recombinant anti-IgE antibody therapy.
When pulmonary infi ltrates co-occur with purulent sputum 
in patients with severe asthma, ABPM should be suspected. 
Isolation of the fungus is necessary to confi rm the diagnosis 
of ABPM. C albicans is frequently recovered from bronchial 
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Table. Clinical, Imaging, and Laboratory Findings
  
    Diagnostic Criteriaa Case
Asthmab Yes
Peripheral blood eosinophilia 1000/µL (reference range,
 800-1200)c
Skin test reactivityd to C albicans
   Skin prick test Positive
   Intradermal test
   (immediate and delayed) Positive
Elevated total IgE levels 531 IU/mL
Presence of serum IgE antibody
to C albicans 2.1 kUA/Le
Precipitating antibody to
C albicans Positive
Isolation of C albicans C albicans in induced sputum
Recurrent pulmonary infi ltrates Yes
Bronchiectasia Peripheral
Exclusion of ABPA as Negative in vivo and
diagnostic consideration in vitro tests
Abbreviations: ABPA, allergic bronchopulmonary aspergillosis; Ig, 
immunoglobulin.
a Modifi ed from Lee TM et al [4].
b
 According to the criteria of the Global Initiative for Asthma 2006. Basal 
spirometry prior to initiation of treatment: forced vital capacity of 2600 
mL (61%) and forced expiratory volume in 1 second of 1540 mL (45%) 
with bronchodilator test >12% and 200 mL.
c Mean of 7 determinations performed when free of oral corticosteroids, 
from 2005 to 2008.
d According to Dreborg S [9].
e Mean value of serum specifi c immunoglobulin E from a pool of 5 patients 
who were allergic to C albicans was 0.41 kUA/L (range, 0.1-3.06/kUA/L).
specimens and erroneously classified as a contaminant. 
Nevertheless, it has been cultured under sterile conditions 
at autopsy, thus suggesting true bronchial colonization [6]. 
Although not as common as ABPA, cases of ABPC have also 
been reported [2-5].
There is evidence that appropriate management of 
ABPA may limit the extent of pulmonary damage and 
improve pulmonary physiology [7]; therefore, other allergic 
bronchopulmonary mycoses could also benefit from the 
same management. Treatment has traditionally been based 
on corticosteroids and, occasionally, itraconazole as a 
corticosteroid-sparing therapy or in patients with a slow 
response to corticosteroids. 
Omalizumab is a recombinant DNA–derived humanized 
IgG1 monoclonal antibody that selectively binds to human IgE. 
It inhibits binding of IgE to the high-affi nity IgE receptor on 
the surface of mast cells and basophils, thus limiting the degree 
of release of mediators and downregulating the presence of 
FcεRI on the surface of these cells. Omalizumab is indicated for 
adults with moderate to severe persistent asthma and positive 
skin test results or in vitro reactivity to perennial aeroallergens 
and whose symptoms are inadequately controlled with inhaled 
corticosteroids. Effi cacy after treatment with recombinant 
anti-IgE antibodies has been reported in ABPA [8], but there 
are no data regarding its effi cacy in other ABPM.
We present a case of ABPC. To the best of our knowledge, 
this is the fi rst report of ABPC successfully treated with 
omalizumab. Although this drug’s indications are currently 
limited to moderate to severe persistent asthma, omalizumab 
and other anti-IgE antibodies could play an increasingly 
important role in high-affi nity IgE receptor diseases.
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Table. Results of a Questionnaire Answered by 132 Patients to Assess 
Their Knowledge of Pollen Information Systems and Interest in Receiving 
Pollen Information Via SMS
   
Knowledge of pollen information systems 80 (60%)
Knowledge of a website that provides 
pollen information 22 (17%)
Knowledge of pollen information 
sent via SMS 20 (15%)
Interest in receiving pollen information 
via SMS 118 (90%)
   – Weekly 47 (36%)
   – Monthly 30 (23%)
   – Daily 22 (17%)
   – Fortnightly 19 (15%)
   – Only in the spring 75 (57%)
   – Throughout the year 37 (28%)
Abbreviation: SMS, short messaging service.
Information on airborne pollen concentrations is invaluable 
for the diagnosis and treatment of allergic diseases. Patients 
who are allergic to pollen can also benefi t from this information, 
especially if they can get an up-to-date or early prognostic 
estimate of pollen concentrations.
Almost the whole population of our Autonomous 
Community owns a mobile telephone. Hence, information 
disseminated via this medium has the potential to reach the 
entire interested population. In this sense, the short messaging 
service (SMS) system may be an appropriate method of 
providing data on the pollen concentrations and forecasts. We 
currently obtain this information from the following sources: 
1) a fixed Burkard volumetric trap, which continuously 
analyzes the atmosphere; 2) 2 portable Burkard volumetric 
traps that take specifi c samples at solar noon; 3) phenological 
observations of the plants that are the principal sources of 
pollen; 4) daily meteorological data; and 5) comparison with 
data from previous years since 1993. The resultant information 
provides a model or pattern for each pollen type [1].
The information obtained is disseminated through the 
research group’s website, http://www.aerouex.es, and during 
2007 and 2008 it was also distributed weekly via SMS without 
charge to people who had registered on the website. The 
message sent included concentrations of total pollen and of the 
3 to 4 most abundant pollen types, indicating current intensity 
and the forecast for the following days.
Between February and March 2008, a survey was 
conducted among patients from the Allergology Department 
of the Infanta Cristina University Hospital in Badajoz to assess 
the level of interest in pollen information and in the possibility 
of receiving this information via SMS (Table).
Between 2007 and 2008, we sent 12 200 SMS, for which 
demand increased steadily. At the end of June 2008, there were 878 
registered users, of whom 85% had provided their mobile telephone 
number to receive the SMS. The greatest increments in registrations 
were observed after local press reports about the system.
The usefulness of information on pollen concentrations 
is widely accepted by allergologists. Furthermore, SMS 
is increasingly used in medicine with various objectives: 
monitoring and treatment of certain diseases, as reminders of 
medical appointments, or to provide information to family about 
hospitalized patients. It has been proven to reduce health care 
costs and improve patient quality of life [2-9]. However, we 
were unable to fi nd data in the literature on the use of SMS as a 
means of providing information to allergic patients. Although 
information on pollen concentrations is also provided via Internet 
in many countries, in Spain, only half the population have access 
to this medium in some Autonomous Communities [10].
The cost of sending messages to mobile phones can be borne 
institutionally or by the person interested in receiving them. 
Indeed, it could be argued that institutional involvement would be 
justifi ed if the information provided a social or economic benefi t. 
One option would be to offer the information to interested parties 
at a reasonable price. We continue to offer our information free 
of charge in 2009, and we provide the possibility of receiving the 
information on demand by sending an SMS to the number 5399 
with the word polen in the text. This information is updated daily 
in spring, and weekly for the rest of the year.
In our opinion, SMS is an excellent channel for keeping 
allergic patients informed about pollen concentrations. We found 
that the service was well accepted, although the benefi ts and 
effectiveness should be evaluated using satisfaction questionnaires 
and/or assessment of how the patient controls the illness.
These data were presented in part in abstract and poster form at 
the XXVII Congress of the EAACI, Barcelona, June 7-11, 2008.
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Figure. Natural rubber latex graded challenge.
Allergy to natural rubber latex (NRL) is commonly 
encountered in the allergy clinic. Diagnosis is based on a strong 
history of type I hypersensitivity reaction after contact with 
NRL and supported by the results of skin prick testing (SPT), 
serum specifi c immunoglobulin E (SSIgE), and/or the basophil 
activation test (BAT). Reported sensitivity and specifi city rates 
vary depending upon the extract or kit used, and it is unusual in 
clinical practice for all the diagnostic tests to be negative in the 
presence of a strong clinical history. The combined sensitivity and 
specifi city of the diagnostic tests mentioned above has not been 
reported. BAT showed a sensitivity of 100% in a small group of 
clinically reactive patients with no specifi c IgE demonstrable 
by SPT or SSIgE [1]. In cases where the diagnostic tests are not 
confi rmatory, provocation testing with NRL gloves has been 
recommended [2], despite the potential risk of anaphylaxis. We 
use a locally modifi ed glove use test (Figure). 
To highlight the diffi culties in diagnosing NRL allergy, 
we report 2 patients with a strong history of immediate 
hypersensitivity reactions to latex in the absence of 
demonstrable SSIgE (Pharmacia CAP, Phadia Ltd, Milton 
Keynes, UK), negative SPT (ALK-Abello Ltd, Hungerford, 
UK), negative prick-prick test with an NRL glove, and, in 
1 patient, negative BAT. 
A 53-year-old female health care assistant presented with 
a 5-year history of pruritis and erythema developing within 
minutes of contact with an NRL glove. She also experienced 
proximal urticaria and, on 2 occasions, shortness of breath 
and tightness of the throat. The patient had a history of grass 
pollen allergy and epilepsy. Application of the glove use test 
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on wet hands induced intense pruritis and erythema almost 
immediately, and this extended to the forearm when the test 
was terminated. The BAT result was positive for expression 
of CD63. 
 A 27-year-old female shop assistant had a history of 
recurrent local irritation and swelling after contact with a 
condom. Following normal vaginal delivery in an obstetric unit 
where no NRL avoidance measures were taken, she developed 
signifi cant infl ammation in her genitalia requiring a prolonged 
stay in hospital. She also had a history of mild asthma and 
chronic idiopathic urticaria, which was in remission at the 
time. Application of the glove use test produced no symptoms, 
although rubbing the mucosa of the lip with the NRL glove 
resulted in pronounced swelling. The BAT was negative for 
expression of CD63.
This report demonstrates that immediate hypersensitivity 
to latex can occur in the absence of demonstrable specifi c 
IgE and a negative BAT result. Interestingly, neither case 
showed a positive response to prick-prick skin testing despite 
a positive result with provocation testing using the same 
glove. One possible explanation for this discrepancy is that 
non-IgE–mediated mechanisms may be involved, although 
it is more likely that conventional diagnostic methodologies 
were not sensitive enough to detect specifi c IgE. It is plausible 
that specifi c IgE in these patients is directed against an epitope 
that was either not present at a suffi cient concentration or 
was absent or denatured in the SPT extract and in vitro tests. 
Chromatographic studies to separate the NRL proteins in the 
glove may be used to identify undetermined latex antigens 
in such circumstances. This could pave the way for the 
development of additional diagnostic approaches; however, 
such studies are outside the remit of our clinical service. 
Improved diagnostic testing is necessary because of the 
small yet real risk of anaphylaxis associated with provocation 
testing, which should only be undertaken when the history 
is suggestive and diagnostic test results are indeterminate. 
An accurate diagnosis of latex allergy is paramount, since 
it has important health, occupational, and medicolegal 
implications. 
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Anaphylactic reactions to mango fruit (Mangifera indica) are 
extremely rare, with only 8 cases reported worldwide [1-7].
Mango allergy may occur in isolation or in association with 
pollen or latex allergy [5,8]. One study [9] demonstrated that 
allergens weighing 40, 43, and 67 kDa in mango fruit extract 
were responsible for cross-reactivity to Artemisia pollen, birch 
pollen, celery, and carrot. Another 14-kDa allergen was also 
identifi ed in mango, with cross-reactivity to celery and birch 
pollen, but not to Artemisia.
We report the case of a 39-year-old woman who had an 
anaphylactic reaction immediately after ingestion of fruit 
salad containing fresh mango, strawberry, kiwi, orange, and 
pineapple. She experienced oral allergy syndrome, pruritus of 
the palms, facial angioedema, hoarseness, nausea, vomiting, 
and respiratory distress. She had previously eaten all these 
fruits, except mango, with no allergy symptoms. She was 
admitted to the emergency department, where she received 
adrenaline and corticosteroids, and her clinical condition 
improved. She subsequently ate all the culprit fruits except 
mango, with no reaction. She had allergic rhinitis with 
sensitization to house dust mites and Artemisia vulgaris pollen, 
but no history of asthma, urticaria, or food or latex allergy. 
She denied allergy symptoms to other foods, including celery, 
carrot, anise, cashew, and pistachio nuts.
Skin prick tests (SPT) with commercial extracts and 
prick-to-prick tests (SPPT) with fresh fruit were performed. 
The results were considered positive if the wheal had a mean 
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Figure. Left: SDS-PAGE immunoblotting results for extracts from Lolium perenne pollen (A), Olea europaea pollen (B), Artemisia vulgaris pollen (C), mango 
pulp (D), Betula verrucosa pollen (E). Lane P, patient’s serum; lane C, control serum (pool of sera from non atopic subjects); lane M, molecular mass marker. (-) 
samples without 2-mercaptoethanol (nonreducing electrophoretic conditions), (+) samples with 2-mercaptoethanol (reducing electrophoretic conditions).
Right: SDS-PAGE immunoblotting-inhibition results with mango pulp extract in the solid phase. Lane C, control serum (pool of sera from non atopic 
subjects); lane 1, patient’s serum; lane 2, patient’s serum previously incubated with mango pulp extract (homolog inhibition and positive control of 
inhibition); lane 3, patient serum previously incubated with Artemisia vulgaris pollen extract; lane M, molecular mass marker. SDS-PAGE indicates sodium 
dodecyl sulfate polyacrylamide gel electrophoresis.
diameter ≥3 mm. SPT results were positive for mango (5 mm) 
and negative for strawberry, kiwi, orange, and latex. The results 
of SPPT with fresh fruit were positive for mango (7 mm) and 
negative for strawberry, kiwi, orange, and pineapple.
The serum specifi c immunoglobulin (Ig) E level to mango 
pulp was 5.96 kUA/L and to the other fruits it was <0.35 kUA/L 
(Unicap, Phadia, Uppsala, Sweden). Specifi c IgE levels to 
pollens were as follows: Artemisia vulgaris >100 kUA/L, 
Lolium perenne 0.8 kUA/L, Olea europaea 0.4 kUA/L, and 
Betula verrucosa <0.35 kUA/L.
We considered 2 hypotheses: co-sensitization to mango 
fruit and Artemisia pollen or cross-reactivity between them. 
A sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) immunoblotting assay was carried out under 
reducing and nonreducing conditions. The Artemisia pollen 
extract immunoblot under nonreducing conditions showed 
a broad IgE-binding area in the high molecular weight zone 
and a 17-kDa IgE-binding band. Under reducing conditions, 
the same broad high molecular weight area and a 25-28–kDa 
IgE-binding band were detected. The mango extract revealed 
a 13-kDa IgE-binding band under nonreducing conditions 
and a very faint 15-kDa band under reducing conditions. No 
IgE-binding bands were detected with extracts from Lolium, 
Olea, or Betula pollens. It is possible that the 15-kDa and 
13-kDa bands that appeared in the mango extract under 
reducing and nonreducing conditions could represent different 
electrophoretic behaviors of the same protein, whose tertiary 
structure is altered by the reducing treatment. Cross-reactivity 
was assessed and confi rmed by immunoblotting-inhibition 
assay using mango fruit in the solid phase. When the patient’s 
serum was preincubated with Artemisia vulgaris pollen extract, 
no IgE-binding band was detected in mango fruit.
The patient was therefore diagnosed with mango fruit 
allergy, in the context of a pollen-fruit (Artemisia-mango) allergy 
syndrome manifesting as an anaphylactic reaction. She was 
informed about dietary restrictions and prescribed self-injectable 
adrenaline. The immunological study identifi ed a 13-kDa protein 
from mango fruit involved in this cross-reactivity.
In regions such as southern Europe, where Artemisia pollen 
sensitization is prevalent [10], doctors must be aware of the 
potential role of cross-reactivity between this pollen and mango 
fruit in severe allergic reactions.
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